May 25, 2023 10:24 AM EDT

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Associate Editor

Senior Reporter

Sign up to read this article for free.

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data